Item 7.01 Regulation FD Disclosure.

A copy of the press release, dated July 22, 2021, of Annexon, Inc. (the "Company"), announcing the broadening of the Company's autoimmune franchise with advancement of the Company's third anti-C1q product candidate and strategic expansion into new autoantibody-driven diseases, is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 7.01, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.






Exhibit No.                           Description

99.1            Press Release dated July 22, 2021.

104           Cover Page Interactive Data File, formatted in inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses